Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

American Chemical Society Highlights Modified Citrus Pectin as Solution to Chronic Disease Marker Galectin-3


News provided by

Better Health Publishing

Aug 23, 2012, 07:00 ET

Share this article

Share toX

Share this article

Share toX

SAN FRANCISCO, Aug. 23, 2012 /PRNewswire/ -- Cancer, heart disease, chronic inflammation—these disease conditions plague humanity, causing early death and untold suffering. Slowly, scientists are uncovering their numerous causes including genetic anomalies, environmental toxins, obesity and other factors. However, a rapidly expanding body of research points to a single biological culprit that profoundly affects these and other conditions—the molecule Galectin-3.

Presented at the Annual American Chemical Society Meeting

On August 21, integrative medicine expert Isaac Eliaz, M.D., presented breakthrough research on Galectin-3 and Modified Citrus Pectin (MCP), a therapeutic carbohydrate that helps deactivate this rogue molecule, at the prestigious 244th National Meeting & Exposition of the American Chemical Society (ACS). With over 164,000 active members, ACS is the world's leading scientific society, providing comprehensive access to chemistry-related information, research, funding, networking and education.

Dr. Eliaz's presentation titled, "Galectin-3 and the Role of Modified Citrus Pectin in Health and Disease," was featured as part of the ACS symposium "Renewable Biopolymers: Carbohydrates for Food, Nutrition, Health and Medicine" under the section "Chronic Disease Prevention and Therapy." Dr. Eliaz states, "It is an honor to speak at the prestigious American Chemical Society Meeting and discuss important research regarding Galectin-3 and Modified Citrus Pectin with leaders in the scientific community."

Due to the importance of the topic, Dr. Eliaz's presentation was selected for an ACS sponsored press conference and release.

Galectin-3 in Health and Disease

Dr. Eliaz emphasizes, "At healthy levels, Galectin-3 in the body is no danger at all. It helps regulate cellular growth and cell-to-cell communications. However, too much Galectin-3 can drive cancer growth and metastasis, and is a proven active marker for cardiovascular disease. This protein is involved with two of the world's most prolific killers."

In addition to cancer and heart disease, Galectin-3 has also been directly linked with the progression of chronic inflammation and fibrosis of organs and tissues, such as chronic hepatitis, kidney disease, diabetes and other degenerative conditions.

In his presentation, Dr. Eliaz described Galectin-3 and how its overabundance contributes to disease. He presented breakthrough data from a ten-year population study demonstrating that Galectin-3 levels can predict mortality regardless of age or condition. Elevated Galectin-3 can also help evaluate prognosis and clinical outcome in cancer and heart disease. In cancer patients, higher levels of Galectin-3 in the body signal a more aggressive cancer and reduce the odds of survival, as excess Galectin-3 promotes cancer cell adhesion, aggregation, tumor growth, metastasis, angiogenesis and the inhibition of programmed cell death (apoptosis).

Galectin-3 Blood Test

Recently, the FDA approved a blood serum test to easily measure circulating Galectin-3 levels. This test is covered by most health insurances for the screening of cardiovascular disease, and can also be used to evaluate the risk and prognosis of cancer and other diseases linked to chronic inflammation and fibrosis. Dr. Eliaz notes that this test is an excellent tool in the management of these and other related diseases, but emphasizes that without a solution to combat excess Galectin-3, the test may be arbitrary for some doctors and patients. However, extensive research demonstrates Modified Citrus Pectin (MCP) to be the first proven solution to address elevated Galectin-3. MCP stands out as the only therapeutic agent capable of entering the blood stream to bind and block excess Galectin-3 throughout the body.

The Numerous Benefits of Modified Citrus Pectin

Derived from citrus peels, MCP is an enzymatically modified form of pectin which has a natural affinity for Galectin-3. Numerous published studies demonstrate MCP's effectiveness against cancer through its natural lectin-binding affinity which allows it to bind to excess Galectin-3 and block its harmful effects. MCP also demonstrates powerful immune enhancement benefits and is also proven to remove heavy metals from the body without affecting essential minerals.

"Modified citrus pectin performs a number of remarkable tasks," says Dr. Eliaz. "By binding and blocking Galectin-3, it blocks cancer cell aggregation, keeps cancer cells from docking with blood vessels and prevents angiogenesis, the blood vessel development so crucial to cancer metastasis."

Dr. Eliaz shared key research highlights from numerous published studies demonstrating MCP's powerful anticancer activity and its synergy with other anticancer therapies. One of the most recent 2012 studies, published in Cell Biology International, showed that MCP vastly improved the effects of Doxorubicin, allowing for lower doses of the toxic chemotherapy to be used more effectively. He also shared published research demonstrating MCP's ability to enhance the effects of two anticancer botanical formulas, for breast and prostate cancer. Other evidence has shown that MCP advances treatment against chemotherapy-resistant cancers and can protect against cellular damage often caused by chemotherapy and radiation.

"Because cancer tends to become resistant to a single treatment, MCP has become an important component in integrative anti-cancer protocols," says Dr. Eliaz. "It has been proven effective in multiple studies, without toxic side effects."

In the lecture, Dr. Eliaz continued to illuminate how MCP can enhance immunity, remove environmental toxins from the body and help protect against injury. Overall, he stressed the significance of Galectin-3 as a disease biomarker.

"This protein has been associated with many chronic and life threatening conditions, most notably cancer and heart disease," says Dr. Eliaz. "By measuring the amount of Galectin-3, and using MCP to block the harmful effects of this rogue molecule, we can do much to help treat and prevent a number of life threatening illnesses."

For more information on Modified Citrus Pectin call (707) 583-8619, or email [email protected].

About Better Health Publishing:

Better Health Publishing (BHP) focuses on the publication of key works promoting health and wellness. BHP believes that education and accessible information are the core components of a healthy and sustainable society.

This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.

SOURCE Better Health Publishing

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.